The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. - Wikidata - awgldk - TriplyDB

The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.

The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.

http://www.wikidata.org/entity/Q34345557

about

Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL)The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity Increased copy number at 3p14 in breast cancer A HaemAtlas: characterizing gene expression in differentiated human blood cells LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy Assembly of Neuronal Connectivity by Neurotrophic Factors and Leucine-Rich Repeat Proteins Understanding epithelial homeostasis in the intestine: An old battlefield of ideas, recent breakthroughs and remaining controversies In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear Lrig3 regulates neural crest formation in Xenopus by modulating Fgf and Wnt signaling pathways Lrig2-deficient mice are protected against PDGFB-induced glioma LIG family receptor tyrosine kinase-associated proteins modulate growth factor signals during neural development Cross-repressive interactions between Lrig3 and netrin 1 shape the architecture of the inner ear.Identification of beta-secretase (BACE1) substrates using quantitative proteomics.Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis.Reexpression of LGI1 in glioma cells results in dysregulation of genes implicated in the canonical axon guidance pathway.A human pluripotent stem cell surface N-glycoproteome resource reveals markers, extracellular epitopes, and drug targets.Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response.Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction.Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling.The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor The LRIG family: enigmatic regulators of growth factor receptor signaling.The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2 Slitrks as emerging candidate genes involved in neuropsychiatric disorders Epiprofin orchestrates epidermal keratinocyte proliferation and differentiation Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field MicroRNA-19a promotes glioma cell growth by repressing LRIG1 Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum LRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasia Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia.Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.LRIG and cancer prognosis.LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling LRIG1 Regulates Ontogeny of Smooth Muscle-Derived Subsets of Interstitial Cells of Cajal in Mice.Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma.Intracellular LINGO-1 negatively regulates Trk neurotrophin receptor signaling.Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.Slitrk5 Mediates BDNF-Dependent TrkB Receptor Trafficking and Signaling.LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression.

P2860

Q21562355-C8BAE603-6194-45AE-BFEE-3D5F4AA4105E Q24314999-BFE38CC7-7E2E-4EFC-8EB0-196B03B12A72 Q24530212-D19D7B52-79DF-4D74-8094-894E1C088F77 Q24646314-B994B1D3-B4C5-4214-BA2F-8E5D1A3E9E4C Q24681561-C5094A9C-F08E-471E-BCDF-E8579F369C6A Q26739532-D9AA65B8-3D2C-428B-9C53-81C145D93252 Q26991584-91C97986-9A8C-4F61-A46C-D98EF4853C9B Q27320101-A3EDD9C5-8CF7-407B-89F5-7CBC789843E8 Q28312188-2DCB32B9-5A90-427B-9B54-FFD91A24289A Q28506352-48CFB85A-DC92-4DEA-A71B-D0E721280C88 Q28594886-FF4DDBA2-BAFE-44A0-9E8A-2E89DC62E422 Q30435788-E5F9A1B5-A1A8-4EBA-BA82-E4089EFBD70E Q33521280-3DDB2698-5948-4417-A0DA-44251D64DECC Q33529059-6F079833-2E17-4BF2-8BB1-8C3B38949AC6 Q33653166-20611645-5DD6-43BD-AC45-DF84C9551D26 Q33949177-B97D38E5-78AF-4103-A9ED-F7EFB78288E1 Q34100283-C0B0655D-7B6C-4095-B134-DC5706C7D4CF Q34149773-30F79E78-BEDE-4454-82EF-F83EE2134ADE Q34258498-EE308DCD-AE21-4034-876E-007626FAC176 Q34264864-0AC6AC3D-549F-4527-99E8-B93506A63205 Q34276176-EBEBE707-1DCC-498A-B79A-64AFFAB21251 Q34349389-62A09A02-D3BF-4635-92C6-4D7FDDA97206 Q34421021-E1FE1CF7-0AD5-42E5-9ED2-0103ABD098B9 Q34634305-E8A1C2E1-2CDA-4377-9F77-4F4E7A3304EC Q34698562-7D91CCFB-400B-4704-BFA6-E612696B4B27 Q34996130-B3D7FFDE-AE74-402F-B548-A29559282F3C Q35017058-1F5DFA9F-4592-4424-A947-9C53F90414DE Q35096647-28F81B60-A0C7-4282-9851-2B561C240D67 Q35141723-F3040F53-1CDE-4AD4-AC98-D06DBDF763FE Q35236469-7B0E2AE0-2DC2-48E4-9CA9-AF653AC94554 Q35386137-3284FCE7-3EDD-4BFE-9F98-34E4E27C6DE1 Q35626430-DB75DB58-13E0-459F-8ACB-86527592B86D Q35803259-A6738895-2807-4FCC-BF72-D9DD4201EEC3 Q35923693-033AD5CB-679E-4DF9-92AF-B0873269FE03 Q36165800-A7B06D3A-E039-41BB-9A57-EBDFA444906C Q36421275-44BED717-97B7-4C08-A4DE-74432B960FF2 Q36437261-A0661234-AC2A-4765-81BE-3EAA0403093A Q36668929-6EB3EBA3-C1E6-4449-8F0C-A81182E2389A Q36723368-6E01D92E-C4BA-4F93-BC71-40FF09F212A7 Q36732552-054D7BFC-7B36-4DCE-A256-6119DBF5CD56

P2860

The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.

http://www.wikidata.org/entity/Q34345557

description

2004 nî lūn-bûn

@nan

2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@ast

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@en

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@nl

type

label

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@ast

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@en

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@nl

prefLabel

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@ast

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@en

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@nl

P1433

Q34345557-C6D46A77-E970-44F5-98A6-D564FC5527A9

P1476

Q34345557-C78C0203-E38E-46BE-A72B-55FE43F175C4

P2093

Q34345557-004C96C9-75F6-4462-B566-D4CE71906D8C

Q34345557-091F7933-88B7-4BA2-B924-9E852B0C454D

Q34345557-33C7311D-4246-4E8C-A323-E9A715280613

Q34345557-45EB04BC-C835-4D5E-8963-703D54B97AEA

Q34345557-A5E54658-1221-44AB-8F66-A767498DD85E

Q34345557-AC4B6824-7C42-4654-8D5C-11EDFAE8764E

Q34345557-B5B5FBA6-3408-4476-AA3D-97C8357A1410

P2860

Q34345557-054D5845-93C7-4203-818A-6121B2360F0B

Q34345557-0B165CF4-4501-477D-8D07-099D3750C8DB

Q34345557-20CA2106-F625-4701-A431-9387A7F6576C

Q34345557-21813B5B-8CC1-42D4-B136-9AB3A7476A90

Q34345557-23F20947-308A-4D8B-8FDA-128DD723D4F3

Q34345557-2BD79BB8-860C-4CEA-8308-C6267AE42503

Q34345557-2DF08EEE-7F43-427C-BCF5-E7A944E89667

Q34345557-2F429388-4B0A-4B4D-9070-D130461CC91E

Q34345557-651E918A-6B0A-4837-908B-BAC3D0965423

Q34345557-6E94A09C-7193-4FAD-8ACD-896C7EDA7CBA

P304

Q34345557-0BFC44BD-8994-4DB4-90EB-0731385F2D29

P31

Q34345557-A2650EA9-2204-4458-8082-E2F583FD812D

P356

Q34345557-759B188E-7B66-42BB-B6CA-C35234D45758

P407

Q34345557-5608362A-2CA6-4BFE-A760-0E74AC631A0E

P433

Q34345557-D59C5264-951E-4D27-94B9-216ED6A0C2B7

P478

Q34345557-C3645120-0D0F-448A-B715-52F640D3FC7D

P577

Q34345557-60435BAA-AEB5-4D1D-9537-7F2A1857979E

P698

Q34345557-12136C61-3483-4536-82AA-1174210A1BFD

P356

P1433

Journal of Biological Chemistry

P1476

The leucine-rich repeat protei ...... ily receptor tyrosine kinases.

@en

P2093

Colleen Sweeney

http://www.w3.org/2001/XMLSchema#string

Ellen Ingalla

http://www.w3.org/2001/XMLSchema#string

Kermit L Carraway

http://www.w3.org/2001/XMLSchema#string

Lily Yen

http://www.w3.org/2001/XMLSchema#string

Melanie B Laederich

http://www.w3.org/2001/XMLSchema#string

Melanie Funes-Duran

http://www.w3.org/2001/XMLSchema#string

Xiuli Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of FLRT1, FLRT2, and FLRT3: a novel family of transmembrane leucine-rich repeat proteins

An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels

LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation

LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis

Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation

Cloning, characterization, and expression of human LIG1.

Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.

Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?

Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers

cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains.

P304

47050-47056

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M409703200

http://www.w3.org/2001/XMLSchema#string

P407

P433

45

http://www.w3.org/2001/XMLSchema#string

P478

279

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15345710

http://www.w3.org/2001/XMLSchema#string